vs
Side-by-side financial comparison of CRA INTERNATIONAL, INC. (CRAI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $197.0M, roughly 1.6× CRA INTERNATIONAL, INC.). Bio-Techne runs the higher net margin — 16.4% vs 6.7%, a 9.7% gap on every dollar of revenue. On growth, CRA INTERNATIONAL, INC. posted the faster year-over-year revenue change (11.6% vs -1.5%). Over the past eight quarters, CRA INTERNATIONAL, INC.'s revenue compounded faster (7.1% CAGR vs 1.3%).
CRA INTERNATIONAL, INC.CRAIEarnings & Financial Report
CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CRAI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.0M | $311.4M |
| Net Profit | $13.2M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | 10.5% | 24.2% |
| Net Margin | 6.7% | 16.4% |
| Revenue YoY | 11.6% | -1.5% |
| Net Profit YoY | -12.0% | 126.0% |
| EPS (diluted) | $1.99 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $197.0M | $295.9M | ||
| Q3 25 | $185.9M | — | ||
| Q2 25 | $186.9M | $317.0M | ||
| Q1 25 | $181.9M | $316.2M | ||
| Q4 24 | $176.4M | $297.0M | ||
| Q3 24 | $167.7M | $289.5M | ||
| Q2 24 | $171.4M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $13.2M | $38.0M | ||
| Q3 25 | $11.5M | — | ||
| Q2 25 | $12.1M | $-17.7M | ||
| Q1 25 | $18.0M | $22.6M | ||
| Q4 24 | $15.0M | $34.9M | ||
| Q3 24 | $11.4M | $33.6M | ||
| Q2 24 | $6.5M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 10.5% | 18.4% | ||
| Q3 25 | 9.3% | — | ||
| Q2 25 | 10.6% | -7.5% | ||
| Q1 25 | 14.0% | 12.2% | ||
| Q4 24 | 12.2% | 16.0% | ||
| Q3 24 | 11.0% | 13.8% | ||
| Q2 24 | 6.6% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 6.7% | 12.8% | ||
| Q3 25 | 6.2% | — | ||
| Q2 25 | 6.5% | -5.6% | ||
| Q1 25 | 9.9% | 7.1% | ||
| Q4 24 | 8.5% | 11.7% | ||
| Q3 24 | 6.8% | 11.6% | ||
| Q2 24 | 3.8% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $1.99 | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $213.6M | $2.1B |
| Total Assets | $628.9M | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $18.2M | $172.9M | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $19.4M | $162.2M | ||
| Q1 25 | $25.6M | $140.7M | ||
| Q4 24 | $26.7M | $177.5M | ||
| Q3 24 | $24.5M | $187.5M | ||
| Q2 24 | $24.6M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $213.6M | $2.0B | ||
| Q3 25 | $201.7M | — | ||
| Q2 25 | $197.0M | $1.9B | ||
| Q1 25 | $227.3M | $2.0B | ||
| Q4 24 | $212.1M | $2.1B | ||
| Q3 24 | $204.5M | $2.1B | ||
| Q2 24 | $191.7M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $628.9M | $2.5B | ||
| Q3 25 | $629.0M | — | ||
| Q2 25 | $606.8M | $2.6B | ||
| Q1 25 | $590.4M | $2.6B | ||
| Q4 24 | $571.4M | $2.7B | ||
| Q3 24 | $582.3M | $2.7B | ||
| Q2 24 | $546.0M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.4M | — | ||
| Q3 25 | $36.5M | — | ||
| Q2 25 | $5.9M | $98.2M | ||
| Q1 25 | $-80.0M | $41.1M | ||
| Q4 24 | $79.4M | $84.3M | ||
| Q3 24 | $31.6M | $63.9M | ||
| Q2 24 | $1.8M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $35.9M | — | ||
| Q2 25 | $4.7M | $93.3M | ||
| Q1 25 | $-81.0M | $31.0M | ||
| Q4 24 | $68.8M | $77.5M | ||
| Q3 24 | $28.6M | $54.7M | ||
| Q2 24 | $-509.0K | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 2.5% | 29.4% | ||
| Q1 25 | -44.5% | 9.8% | ||
| Q4 24 | 39.0% | 26.1% | ||
| Q3 24 | 17.0% | 18.9% | ||
| Q2 24 | -0.3% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.5% | 3.2% | ||
| Q4 24 | 6.0% | 2.3% | ||
| Q3 24 | 1.8% | 3.2% | ||
| Q2 24 | 1.4% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.70× | — | ||
| Q3 25 | 3.19× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -4.44× | 1.82× | ||
| Q4 24 | 5.30× | 2.42× | ||
| Q3 24 | 2.76× | 1.90× | ||
| Q2 24 | 0.28× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRAI
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
